EssilorLuxottica faces cautious analyst tone, shares trade lower in Paris
25.06.2026 - 18:17:43 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 18:16.
EssilorLuxottica (FR0000121667) sits in focus today with a cluster of fresh analyst assessments as the shares trade on Euronext Paris around the mid-160-euro range. The stock reflects a more cautious stance after Deutsche Bank and Jefferies trimmed their price targets this week, according to a dpa-AFX summary cited by finanzen.at and Marketscreener.
What the analysts are saying
On 24 June 2026 Deutsche Bank reiterated its rating on EssilorLuxottica but cut the price target from 183 euros to 181 euros and maintained a "Hold" recommendation, as reported by dpa-AFX and documented by finanzen.at. Jefferies on the same day also reduced its target, setting a new level of 250 euros while keeping a "Buy" stance, which still signals notable upside from current Paris prices around 165 to 166 euros.
Marketscreener’s compilation of analyst commentary highlights that these two target cuts arrive shortly before the upcoming half-year results, with some brokers describing their stance as cautious ahead of new data. For US investors, MarketBeat shows that the unsponsored EssilorLuxottica ADR (ESLOY) closed at 95.44 dollars on 24 June 2026 on the OTC market, down 0.23 percent, underlining that the more muted tone is visible across venues.
Consensus picture and valuation levels
Consensus data aggregated by Investing.com for the Paris ticker ESLX points to a mixed but broadly constructive view, with the average analyst rating close to a "Hold" to "Moderate Buy" band and a blended price target that still implies upside from current levels near 165 euros. Danelfin’s AI-derived score assigns EssilorLuxottica an AI Score of 5 out of 10 today, translating into a neutral "Hold" signal with a 49 percent probability of outperforming the market over the next three months, exactly in line with its global stock universe average.
Valuation metrics remain elevated compared with some peers in the medical products and consumer eyewear space. Hargreaves Lansdown cites a price/earnings ratio of about 57.4 times based on the current share price and reported earnings, together with a dividend yield of roughly 2.37 percent, placing EssilorLuxottica in the bracket of quality growth names where investors accept higher multiples for brand strength and recurring demand.
All news and analysis on the EssilorLuxottica shares
Track recent analyst notes, price moves and corporate disclosures for EssilorLuxottica in one place.
The product and brand engine
EssilorLuxottica generates its revenue mainly by designing, manufacturing and distributing ophthalmic lenses, prescription frames and sunglasses through both wholesale and retail channels worldwide, with major brands including Ray-Ban and Oakley as well as licensed labels such as Prada and Giorgio Armani. The company also runs large optical retail chains in Europe and North America, which gives it direct access to end customers and a recurring stream of lens and frame replacement demand.
Where the shares trade today
The EssilorLuxottica shares (FR0000121667) trade on 2026-06-25 at 10:06 local time on Euronext Paris at 165.85 euros, according to UniCredit’s onemarkets reference quote, which marks a decline of 1.63 percent or 2.71 euros on the day.
Key data on the EssilorLuxottica shares
- Company: EssilorLuxottica Société anonyme
- ISIN: FR0000121667
- WKN: 863195
- Ticker: EL (Euronext Paris: EL FP)
- Trading venue: Euronext Paris
- Price (as of 2026-06-25, 10:06): 165.85 EUR
- Market cap: approximately 78.3 billion EUR (based on a share price around 168.60 euros reported by Hargreaves Lansdown on 25 June 2026).
- Sector / industry: Health Care - Medical Equipment & Supplies / Eyewear and optical retail
- Index membership: Part of major European indices including the CAC 40 via its Paris listing.
- Next earnings date: 2026-07-28 (estimated next results date per MarketBeat company calendar for EssilorLuxottica ADR).
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or a solicitation of any kind. All data and assessments are based on sources believed to be reliable at the time of publication, but completeness and accuracy cannot be guaranteed. Investors should conduct their own research and, where appropriate, seek professional advice before making investment decisions.
